Treating and Preventing Adolescent Mental Health Disorders: Treating and Preventing Adolescent Mental Health Disorders

Home > Table of Contents

Book Title: Treating and Preventing Adolescent Mental Health Disorders > pp. [801]

UNDEFINED: AUTHORS

Treating and Preventing Adolescent Mental Health Disorders

Print ISBN 9780195173642, 2005
pp. [801]

for schizophrenia

in adolescents , 115–16

in adults , 116–17

for substance use disorders , 395–96

for suicide attempters , 40–41

Fat, body, fear of, as criterion for anorexia nervosa , 260

Fear

versus anxiety , 162

of body fat or weight gain, as criterion for anorexia nervosa , 260

brain circuitry for, developmental shifts , 175–76

stranger, absence of, schizophrenia and , 146

Fear structures, in anxiety disorders

cognitive-behavioral therapy and , 184

emotional processing theory and , 171–72

Feeding problems, early, bulimia nervosa and , 312–13

Females . See Gender differences

Financing

for evidence-based mental health services , 554–55

for substance abuse services , 569 , 571 , 572

for suicide prevention evaluation studies , 492–93

Finding Hope and Help program, suicide prevention , 454

Firearms

availability, suicide and , 434 , 435 , 441

restriction programs , 466–69 , 467t–468 t

First (initial) onset, definition , xxxv, 58

Flashback , 371

Flow state

in positive psychology , 508

in positive youth development , 510

Fluid abnormalities, in eating disorders , 276 t

Flunitrazepam abuse , 370

Fluoxetine

for bulimia nervosa , 293

for generalized anxiety disorder , 197

for major depressive disorder

in adults , 42

in children and adolescents , 44 , 45 t, 47–48

with substance use disorder , 409

for obsessive-compulsive disorder , 208

for panic disorder , 202

for phobia , 201–2

for post-traumatic stress disorder , 210

for selective mutism , 189 t, 194

for suicide attempters , 483–84

Flupenthixol, for schizophrenia , 122 t

Fluphenazine, for schizophrenia , 122 t, 125

Fluvoxamine

for major depressive disorder , 42

for obsessive-compulsive disorder , 207–8

for panic disorder , 202

for separation anxiety disorder , 199

for social anxiety disorder , 189 t, 193

Focus on Families Program , 421

Follow-back studies, in schizophrenia , 143–44 , 148–49 , 150 t

Forget Me , 370

FRIENDS program , 239–40

Frontal-temporal circuitry, in schizophrenia , 98–99

Frontal white matter volume, developmental changes , xxix

Functional family therapy, state-level implementation , 556

Future expectations, positive, as outcome of positive youth development , 505

Gamma-band activity, in schizophrenia , 89–90

Gammahydroxybutyrate (GHB), 369–70

Gang affiliation, and anxiety disorders , 229

Gastrointestinal abnormalities, in eating disorders , 276 t

Gatekeeper training, for suicide prevention , 451t–453 t, 453–54

Gateway theory of substance abuse , 359 , 413– 14

Gender differences

anorexia nervosa , 306

anxiety disorders , 168

major depressive disorder , 9 , 27

substance abuse treatment , 562

substance use , 345–46

suicide , 436

Gene expression, hormones and , xxxi

Generalized anxiety disorder , 195

comorbidity , 169 , 169 t

description , 166

genetics , 180 , 180 t

signs and symptoms , 166 t

treatment , 189 t, 214 t

in adults , 194–95

in children and adolescents , 195–98

maintenance of gains , 215

management of partial response and nonresponse to , 218

Genes, susceptibility

in anorexia nervosa , 311–12

in schizophrenia , 103–6

and adolescence , 105–6

identification , 103–5

in substance use disorders , 385

Genetic counseling, in schizophrenia , 107

Genetics , xxxii

anorexia nervosa , 311–12

anxiety disorders , 180–81 , 180 t, 225

bipolar disorder , 24 , 25 t

bulimia nervosa , 314–15

depression , 24 , 25 t

schizophrenia , 82 , 101–7 , 153–54

end p.801